Foundation Medicine CSO Calls for Caution on Clinical Use of ctDNA Assays, CTC Test Development | GenomeWeb

NEW YORK (GenomeWeb) — As a number of companies forge ahead with blood-based cell-free tumor DNA or circulating tumor cell "liquid biopsy" tests for cancer diagnostics, Foundation Medicine is taking a more cautious approach.

"We fundamentally believe that cell-free DNA tests, in the vast majority of clinical settings, should only be used when it's absolutely impossible to get hold of an FFPE biopsy, or that biopsy has been exhausted with the pathology work-up," Foundation Medicine CSO Phil Stephens told GenomeWeb recently.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.